Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Abstract : Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with both response to NET and prognosis.
Type de document :
Article dans une revue
Journal of Hematology & Oncology, 2018, 11 (1), pp.124. 〈10.1186/s13045-018-0670-9〉
Liste complète des métadonnées

https://hal.archives-ouvertes.fr/hal-01930042
Contributeur : Mouniati Colo <>
Soumis le : mercredi 21 novembre 2018 - 15:23:17
Dernière modification le : jeudi 7 février 2019 - 17:53:45

Lien texte intégral

Identifiants

Citation

Xu Liang, Adrien Briaux, Véronique Becette, Camille Benoist, Anais Boulai, et al.. Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609). Journal of Hematology & Oncology, 2018, 11 (1), pp.124. 〈10.1186/s13045-018-0670-9〉. 〈hal-01930042〉

Partager

Métriques

Consultations de la notice

44